Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.3K

Genotypes of hepatitis C virus infection in Bangladeshi population

M S Islam1, M R Miah, P K Roy

  • 1Dr AMM Shariful Islam, Assistant Professor, Department of Gastroenterology, Dhaka Medical College Hospital (DMCH), Dhaka, Bangladesh.

Mymensingh Medical Journal : MMJ
|March 2, 2015
PubMed

Insights

Hepatitis C virus (HCV) genotype 3 is the most common in Bangladesh, affecting over 50% of patients. Understanding HCV genotypes is crucial for effective treatment planning and predicting outcomes in the Bangladeshi population.

Area of Science:

  • Hepatology
  • Virology
  • Epidemiology

Background:

  • Hepatitis C virus (HCV) is a significant global health concern causing chronic liver disease.
  • Limited data exists on the specific HCV genotypes prevalent in Bangladesh.
  • Genotyping is essential for tailoring treatment and predicting patient response.

Purpose of the Study:

  • To determine the distribution of HCV genotypes among diagnosed chronic hepatitis C patients in Bangladesh.
  • To provide baseline data for public health strategies and treatment protocols.

Main Methods:

  • A prospective and retrospective cross-sectional observational study.
  • Inclusion of 417 patients with confirmed chronic HCV infection from January 2010 to March 2011.
  • Data collection from Bangabandhu Sheikh Mujib Medical University and Square General Hospital, Dhaka.

Main Results:

  • HCV Genotype 3 was the most prevalent, found in 50.19% of patients.
  • Genotype 3 & 4 combination (28.77%) and Genotype 1 (14.14%) were the next most common.
  • Genotypes 2, 4, 5, and various mixed genotypes were identified in smaller proportions.

Conclusions:

  • Genotype 3 is the predominant HCV genotype in the studied Bangladeshi population.
  • Identifying HCV genotypes aids in optimizing treatment strategies, predicting response rates, and understanding prognosis.
  • Further large-scale studies are recommended due to the current study's limitations in sample size and study duration.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

19.0K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
257
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
158